COVID-19 trials registries data warehouse

https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002211-21/CZ

St George Street Capital Ltd - Clinical Trials

info@sgscapital.org

2020-11-30

Completed

RCT

Randomized

Parallel

Blind label

multi-center

Treatment

1. Male or Female. 2. Aged 18 and older. 3. Have either T1DM or T2DM. 4. Hospitalised with suspected or confirmed novel coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)) infection at time of enrolment, categorised as stage 3, 4 or 5 on the WHO Ordinal Scale for Clinical Improvement. 5. Blood glucose level at or above 4 mmol/L. 6. Able to take oral (tablet) formulation of medication. 7. Patient is able to provide written informed consent prior to initiation of any study procedures.

1. In the opinion of the clinical team, progression to intubation or mechanical ventilation is imminent and inevitable, within the next 24 hours, irrespective of the provision of treatments. 2. Patients admitted with primary suspected or proven Mycoplasma pneumoniae, Chlamydia pneumoniae and bacterial pneumonia, who acquired COVID-19 while hospitalized. 3. Treatment with immunomodulators or anti-rejection drugs within the last 3 months. 4. Pregnant or breast feeding. 5. Men, and women of child-bearing potential, unwilling to use highly effective contraception during their participation in the trial and for 2 weeks after study completion. 6. Anticipated transfer to another hospital which is not a study site within 72 hours. 7. Known sensitivity to any of the study medication/placebo excipients. 8. Prior dosing with AZD1656 on a previous clinical trial. 9. Patients admitted as a result of and receiving immediate treatment for an acute asthmatic attack, acute myocardial infarction, acute cerebrovascular event. 10. Any known non-COVID-19, non-diabetes related, serious condition which, in the opinion of the clinical team, makes the patient unsuitable for the trial. 11. Known history of drug or alcohol abuse within previous 12 months of screening. 12. Known history of HIV, hepatitis C or unresolved hepatitis B or severe liver disease. 13. Current or planned use of gemfibrozil or any other strong inhibitors of CYP2C8. 14. Current or previous participation in another clinical trial where the patient has received a dose of an Investigational Medicinal Product (IMP) containing small molecule treatment(s) within 30 days or 5 half-lives (whichever is longer) prior to enrolment into this study, or containing biological treatment(s) within 3 months prior to entry into this study.

2

St George Street Capital Ltd

18

100

United Kingdom

Moderate disease at enrollment

3: Moderate disease at enrollment

40

Clinical Improvement measured as the percentage of subjects at Day 14 who are in categories 1-3 according to the World Health Organization (WHO) 8-point Ordinal Scale for Clinical Improvement, comparing AZD1656 treatment to placebo.

Declared number of arm (3.0) differs from found arms (2.0)

Phase 2

[{"arm_notes": "", "treatment_id": 162, "treatment_name": "Azd1656", "treatment_type": "Metabolic agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]